Top 50 Biotechnology Startup Investors in Belgium (September 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
PMV
VC Fund
|
23 | Belgium, United States, The Netherlands | Seed, Series A, Series B | Software, Biotechnology, Health Care | $1M–$43M |
|
Meusinvest (Noshaq)
VC Fund
|
18 | Belgium, France, Germany | Series A, Seed, Venture - Series Unknown | Biotechnology, Health Care, Medical | $137k–$16M |
|
V-Bio Ventures
VC Fund
|
16 | Belgium, France, United States | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.1M–$88M |
|
Gemma Frisius Fund
VC Fund
|
15 | Belgium, France, United Kingdom | Seed, Series A, Series B | Biotechnology, Medical, Software | $500k–$84M |
|
VIB
VC Fund
|
14 | Belgium, Brazil, Denmark | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.1M–$84M |
|
S.R.I.W.
VC Fund
|
13 | Belgium, United States, Spain | Venture - Series Unknown, Series A | Health Care, Biotechnology, Manufacturing | $422k–$51M |
|
Qbic Fund
VC Fund
|
13 | Belgium, The Netherlands | Seed, Series A | Biotechnology, Software, Health Care | $1.3M–$34M |
|
Vives Louvain Technology Fund
VC Fund
|
9 | Belgium, France, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $156k–$125M |
|
Limburgse Reconversie Maatschappij
VC Fund
|
8 | Belgium, The Netherlands, United States | Seed, Series A | Information Technology, Software, Biotechnology | $658k–$11M |
|
Gimv
VC Fund
|
8 | Belgium, United States, France | Series B, Series A | Biotechnology, Health Care, Medical | $3.3M–$79M |
|
Capricorn Partners
VC Fund
|
8 | Belgium, The Netherlands, United States | Series A, Series B | Biotechnology, Health Care, Software | $3.3M–$45M |
|
KBC
VC Fund
|
7 | Belgium, United States, The Netherlands | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Software | $425k–$65M |
|
Newton Biocapital
VC Fund
|
7 | Belgium, Japan, France | Series A, Venture - Series Unknown, Seed | Biotechnology, Medical, Pharmaceutical | $1.3M–$84M |
|
Vesalius Biocapital Partners
VC Fund
|
7 | Belgium, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $3.9M–$100M |
|
EQT Life Sciences
VC Fund
|
6 | United States, The Netherlands, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $7.3M–$165M |
|
Sambrinvest
VC Fund
|
6 | Belgium, France, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $544k–$49M |
|
Annie Vereecken
Angel
|
5 | Belgium | Seed, Series A, Venture - Series Unknown | Medical, Biotechnology, Hospital | $2M–$30M |
|
Spinventure
VC Fund
|
5 | Belgium | Series A, Seed, Venture - Series Unknown | Biotechnology, Health Care, Medical | $794k–$15M |
|
Innovation Fund
VC Fund
|
4 | Belgium, France, Luxembourg | Seed, Venture - Series Unknown, Series A | Health Care, Manufacturing, Chemical | $318k–$8.8M |
|
Qbic
VC Fund
|
4 | Belgium | Seed, Series B | Health Care, Biotechnology, AgTech | $3.7M–$12M |
|
Omnes Capital
VC Fund
|
4 | France, Germany, United States | Series A, Series B | Software, Biotechnology, Health Care | $4.3M–$53M |
|
Novo Holdings
VC Fund
|
4 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.5M–$135M |
|
Droia Ventures
VC Fund
|
4 | United States, Belgium, The Netherlands | Series A, Series B, Series C | Biotechnology, Medical, Therapeutics | $12M–$130M |
|
Baekeland Funds
VC Fund
|
4 | Belgium | Series B, Series C | Biotechnology, Hardware, Software | |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
4 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
UCB Ventures
VC Fund
|
4 | United States, Belgium, Spain | Series A, Series B, Venture - Series Unknown | Biotechnology, Health Care, Medical | $7M–$135M |
|
Mérieux Equity Partners
VC Fund
|
4 | France, United States, Spain | Series A, Private Equity, Series B | Health Care, Biotechnology, Medical | $5.7M–$150M |
|
Agri Investment Fund
VC Fund
|
3 | Belgium, United Kingdom, Switzerland | Seed, Series B, Series A | Biotechnology, Agriculture, AgTech | $2.9M–$24M |
|
Forbion Capital Partners
VC Fund
|
3 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $16M–$180M |
|
Fund+
VC Fund
|
3 | Belgium, United States, Spain | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$401M |
|
SFPIM
VC Fund
|
3 | Belgium, France, Switzerland | Series A, Venture - Series Unknown | Biotechnology, Health Care, Semiconductor | $8.6M–$251M |
|
GoBeyond
VC Fund
|
3 | Switzerland, Germany, United Kingdom | Seed, Series A | Software, Health Care, Information Technology | $495k–$5M |
|
Theodorus III
VC Fund
|
3 | Belgium, Canada, France | Series A, Seed, Venture - Series Unknown | Health Care, Biotechnology, Software | $67k–$41M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
3 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $850k–$31M |
|
VIVES Funds
VC Fund
|
3 | Belgium, France, Switzerland | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $2.9M–$165M |
|
Fountain Healthcare Partners
VC Fund
|
3 | Ireland, United States, France | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $3.3M–$110M |
|
Inventures SA
VC Fund
|
3 | Belgium, France, United Kingdom | Series A, Seed, Series B | Health Care, Software, Biotechnology | $67k–$21M |
|
AdBio partners
VC Fund
|
3 | France, Spain, Belgium | Seed, Series A, Venture - Series Unknown | Biotechnology, Health Care, Pharmaceutical | $2.2M–$37M |
|
BioGeneration Ventures
VC Fund
|
3 | The Netherlands, United States, Belgium | Series A, Seed | Biotechnology, Therapeutics, Health Care | $1.1M–$86M |
|
Eli Lilly
VC Fund
|
2 | United States, United Kingdom, Canada | Series A, Series B | Biotechnology, Health Care, Medical | |
|
invest.bw
VC Fund
|
2 | United States | Seed | Health Care, Neuroscience | |
|
Capital-E
VC Fund
|
2 | Belgium, United States, Germany | Series B, Series A | Software, Manufacturing, Semiconductor | $3.3M–$26M |
|
M Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
SFPI-FPIM
VC Fund
|
2 | Belgium, United States, The Netherlands | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $4.3M–$250M |
|
Quest for Growth
VC Fund
|
2 | Belgium, France, The Netherlands | Series B, Series C | Biotechnology, Hardware, Software | $510k–$65M |
|
Sofinnova Investments
VC Fund
|
2 | United States, France, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $7.3M–$150M |
|
New Science Ventures
VC Fund
|
2 | United States, United Kingdom, Belgium | Series B, Series A, Series D | Biotechnology, Health Care, Medical | $4M–$52M |
|
Spreds
VC Fund
|
2 | Belgium, France | Series A, Seed, Pre-Seed | Information Technology, E-Commerce, Health Care | $150k–$2.5M |
|
Sofinnova Partners
VC Fund
|
2 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6.6M–$109M |
|
Vinnof
VC Fund
|
2 | Belgium, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $9.3M–$11M |
| Access all 320 investors in Belgium Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Do and dare company
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 159
- Round size: Seed $1M–$4M; Series A $3M–$40M; Series B $6.6M–$43M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
- Borro — Cashless deposit system
- Storm — Storm is een producent van hernieuwbare energie. Samen met ons team ontwikkelen, bouwen en exploiteren we duurzame energieprojecten over het hele land: van wind- en zonneparken tot snellaadstations en batterijopslag. Dit telkens tegen een zo laag mogelijke maatschappelijke kost.
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Venture - Series Unknown
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 82
- Round size: Seed $137k–$6M; Series A $3.6M–$16M; Venture - Series Unknown $2M–$16M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: Belgium, France, United States
Investor stats
- Total investments: 45
- Round size: Seed $3.1M–$50M; Series A $6.9M–$70M; Series B $12M–$88M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $131M in 2021
Portfolio highlights
- Animab — Animal Health Company
- RootWave — RootWave is an electronics company that develops tools that kill weeds it enables farmers to control weeds on their farm. Its technology is an alternative substitute for herbicides and other weed control chemicals. The company was founded in 2012 and headquartered in Warwickshire, United Kingdom.
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
Gemma Frisius Fund KU Leuven is a seed capital fund that aims to stimulate the creation and growth of university related spin-off companies.
Show more...Investment focus
- Industry: Biotechnology, Medical, Software
- Stage:Seed, Series A, Series B
- Geography: Belgium, France, United Kingdom
Investor stats
- Total investments: 41
- Round size: Seed $500k–$4.7M; Series A $932k–$84M; Series B $4.7M–$24M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Runeasi — The first scientifically validated wearable solution to measure impact while running and detect how your body responds to it - Perform real-time biomechanical assessments - Guide your athletes and patients with actionable insights to help them run more efficiently and recover from injuries with confidence
- Optiflux — Optiflux automatiseert het bewaarbeheer van vers fruit met slimme AI & vision-technologie. Minder verlies, meer winst voor teler & handelaar.
- Aspect Analytics — Beyond bioinformatics. Building intelligent platform solutions for mass spectrometry imaging data analysis. #AI4MSI
Strategic research in on life sciences and biotechnology
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: Belgium, Brazil, Denmark
Investor stats
- Total investments: 28
- Round size: Seed $3.1M–$11M; Series A $6.8M–$84M; Series B $4.7M–$65M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
- MRM Health NV — MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications.
- Rainbow Crops — Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties.
The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century. Since its creation in 1979, the Société Régionaled’Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Venture - Series Unknown, Series A
- Geography: Belgium, United States, Spain
Investor stats
- Total investments: 111
- Round size: Series A $422k–$31M; Venture - Series Unknown $2.7M–$51M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Univercells — Mix parlay, atau lebih dikenal sebagai parlay bola atau hanya parlay, merupakan taruhan judi bola online yang menggabungkan minimal 2 hingga 10 tim pertandingan sepak bola menjadi 1 tiket taruhan.
- Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
- Santero Therapeutics — This is the homepage of the website
The Qbic Fund is a multi-sector fund supporting spin-off companies of the Ghent, Brussels and Antwerp university associations and of VITO. Through its strategic partnership with the universities of Ghent, Brussels and Antwerp, and VITO, the Qbic Fund has early and privileged access to promising research projects at these partner universities. Ourinvestment approach is based on early in-depth and independent review and analysis followed by hands on involvement and support.In May 2012 the Qbic Fund held its first close and currently it has over € 30 million under management. The Qbic Fund is backed by several public and private investors and managed by Qbic Venture Partners.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Series A
- Geography: Belgium, The Netherlands
Investor stats
- Total investments: 62
- Round size: Seed $1.3M–$7.4M; Series A $1.6M–$34M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $54M in 2022
Portfolio highlights
- Firecell — Firecell is a Telecommunications Industry.
- Eyeo — eyeo revolutionizes imaging with color splitter sensors. Capture sharper, brighter images in low light using optical waveguide innovation, discover how it works
- Sightera Biosciences — Revolutionizing drug discovery through AI-powered analysis of patient-derived models for breakthrough therapeutics in cancer and regenerative medicine.
Vives is an interregional seed and early stage technology multi-sector fund. The new fund, initiated by UCLouvain, is a unique European inter-university fund having access to world class innovations from leading EU top universities.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: Belgium, France, United States
Investor stats
- Total investments: 27
- Round size: Seed $1.6M–$7.3M; Series A $156k–$49M; Series B $4.7M–$125M
- Lead/follow: 4% lead, 96% follow
- Last fund: May invest from a new fund soon — raised $38M in 2020
Portfolio highlights
- BOTALYS — BOTALYS uses an innovative Biomimetic Indoor Farming technology to recreate the ideal wild conditions for rare botanicals to grow in. We develop pristine & potent botanical ingredients for the Nutraceutical and Cosmetic industries.
- Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Oxygen for growth - LRM
Show more...Investment focus
- Industry: Information Technology, Software, Biotechnology
- Stage:Seed, Series A
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 98
- Round size: Seed $658k–$5.2M; Series A $1.6M–$11M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Monsana — Monsana's AI-powered platform empowers both patients and healthcare professionals in their search for the perfect clinical trial. Each eligibility criterion is validated based on your unstructured textual medical records, allowing highly accurate matching with experimental treatments.
- ADLC — ADLC employs drone technology to deliver logistics services, allowing businesses to implement drone-based solutions without having to manage them in-house. The company is focused on enhancing last-mile delivery in maritime and offshore environments. ADLC now conducts drone delivery services in the Port of Antwerp in collaboration with SGS, atesting and certification company, and works with companies such as BASF. Its drones have reduced delivery times and environmental effect, boosting efficiency sixfold and lowering CO2 emissions by up to 80% for petrochemical sample deliveries.
- Optiflux — Optiflux automatiseert het bewaarbeheer van vers fruit met slimme AI & vision-technologie. Minder verlies, meer winst voor teler & handelaar.
Gimv, a trusted European investment company, helps mid-market businesses create sustainable value through growth capital and expertise across diverse sectors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: Belgium, United States, France
Investor stats
- Total investments: 171
- Round size: Series A $3.3M–$79M; Series B $8.8M–$73M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $838M in 2010
Portfolio highlights
- spineart — Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients.
- ActoGeniX — ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.
- NovoPolymers — NovoPolymers NV is a company, with the vision and mission to develop and produce sustainable solutions for primarily the photovoltaic market.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 121
- Round size: Series A $3.3M–$18M; Series B $5.3M–$45M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fresh fund, raised $53M in 2025
Portfolio highlights
- Endo Tools Therapeutics — Endo Tools Therapeutics is dedicated to the development of innovative devices that provide therapeutic interventions for gastric conditions
- Delft Advanced Biorenewables — We enable the bio-economy by improving the productivity of fermentations with our in-situ product recovery (ISPR) technology.
- Trillium Renewable Chemicals — Trillium Renewable Chemicals manufactures chemicals from renewable feedstocks used in a variety of industrially important applications. The company was founded in 2021 and based in Knoxville, Tennessee.
KBC Private Equity - the investment company of KBC Group - provides development capital and finances buy-outs to medium-sized companies in Belgium and in Central and Eastern Europe, KBC's home markets.Boasting an experienced team of 28 people, it has more than 60 active investments in portfolio with a market value in excess of EUR 400million.KBC Private Equity aims to become one of the leading private equity providers on KBC Group's home markets. As an active shareholder with a long-term perspective, KBC Private Equity is involved in taking strategic decisions and providing support to management teams.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Pre-Seed
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 37
- Round size: Seed $529k–$8M; Pre-Seed $425k–$1.9M; Series A $3M–$65M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Qivalis — Qivalis is a financial technology company designed for payments, settlements, and financial services.
- Octave — Optimize energy use with Octave's battery storage (BESS) and energy management system (EMS). Reduce costs, increase flexibility.
- Ion Beam Applications — Ion Beam Applications is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticalssegment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry.
Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors.
Show more...Investment focus
- Industry: Biotechnology, Medical, Pharmaceutical
- Stage:Series A, Venture - Series Unknown, Seed
- Geography: Belgium, Japan, France
Investor stats
- Total investments: 22
- Round size: Seed $2.9M–$3.2M; Series A $6.1M–$84M; Venture - Series Unknown $1.3M–$20M
- Lead/follow: 68% lead, 32% follow
- Last fund: Likely still investing — raised $57M in 2022
Portfolio highlights
- Bioxodes — Bioxodes is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics to prevent thrombotic events without hemorrhagic risk.
- Tensegrity Pharma — Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.
- Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Belgium, Germany, France
Investor stats
- Total investments: 61
- Round size: Series A $3.9M–$20M; Series B $4.4M–$26M; Series C $7M–$100M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $103M in 2023
Portfolio highlights
- Nutrium — Nutrium is the most up-to-date nutrition software for dietitians and nutritionists to manage their nutrition business with nutritional assessment, meal planning and progress tracking.
- ENYO Pharma — ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public).The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and theBSL4 laboratory Inserm-Jean Mérieux.ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules.The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials.
- Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, The Netherlands, Switzerland
Investor stats
- Total investments: 189
- Round size: Series A $7.3M–$78M; Series B $11M–$114M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $282M in 2023
Portfolio highlights
- ActoGeniX — ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.
- Neurent Medical — Discover NEUROMARK, a minimally invasive solution for Chronic Rhinitis that targets the posterior nasal nerve to provide lasting symptom relief.
- Rotation Medical — Rotation Medical Inc. manufactures and markets a collagen scaffold for rotational cuff disease in Minnesota. The company was formerly known as Denali Medical Inc. and changed its name to Rotation Medical Inc. in March 2010. Rotation Medical was founded in 2009 and headquartered in Plymouth, Minnesota.
Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: Belgium, France, Spain
Investor stats
- Total investments: 40
- Round size: Seed $544k–$24M; Series A $1M–$49M; Series B $4.4M–$45M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Brenus Pharma — Brenus Pharma develops off-the-shelf, next-generation in vivo immunotherapies designed to unlock the immune response against solid tumors.
- Vertical Compute — Vertical Compute offers chiplet-based technology that cuts data movement to achieve up to 80% energy savings.
- Enodia Therapeutics — Enodia Therapeutics pioneers targeted protein degradation at the Sec61 translocon, developing small-molecule therapies for inflammatory and autoimmune diseases.
Annie Vereecken
Show more...Investment focus
- Industry: Medical, Biotechnology, Hospital
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Belgium
Investor stats
- Total investments: 7
- Round size: Seed $2M–$6M; Series A $9.2M–$30M; Venture - Series Unknown $4.1M–$8.8M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Ziphius — Ziphius Vaccines is a biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases.
- Sensolus — Sensolus provides care-free tracking of your valuable non-powered assets directly from the cloud.Sensolus offers turnkey solutions for wireless, low-power context-aware sensing. Sensolus developed a personal product line of low-power tracker systems called STICKNTRACK.Sensolus is built upon many years of expertise in low-power networks,wireless sensor design, cloud-based sensor management, analytics, and applications.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Spinventure supports the creation of spin-off companies that aim to industrialize and commercialize the result of scientific research. Spinventure was born from a collaboration between MEUSINVEST and the University of Liège. It is headquartered in Angleur, Belgium.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Venture - Series Unknown
- Geography: Belgium
Investor stats
- Total investments: 7
- Round size: Series A $794k–$15M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Dim3 — Improve patients outcome - Deliver actionable insights - Save healthcare costs
- Cell Matters — Cell Matters specializes in cell therapy productivity, turning cryopreservation into a competitive advantage. It offers an integrated set of GMP services, in line with regulatory, quality, and GMP requirements of the cell therapy industry.
- Convert Pharmaceuticals — Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors.
Chemical, Advanced Materials, Cosmetics, Recycling, CleanTech, Plastics and Rubber Manufacturing, Nanotechnology, Biosciences
Show more...Investment focus
- Industry: Health Care, Manufacturing, Chemical
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Belgium, France, Luxembourg
Investor stats
- Total investments: 31
- Round size: Seed $318k–$6M; Series A $2.3M–$5M; Venture - Series Unknown $1.1M–$8.8M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
- Fyteko — For a more sustainable agriculture
- Graftys — Graftys, an Aix-en-Provence, France-based early stage company focused on advanced bone biologics.
Qbic is the result of a lot of thinking, debating and sketching of what a city hotel could be; one that breaks the rules and makes people smile.An astonishing level of change has swept through the world over the last few years. But the hotel experience is no different than it’s ever been: stuffy, over-priced and lacking soul. They’re here tochange all that. they’re curious, imaginative and friendly, and they think there are lots of people just like us seeking a hotel with personality in the middle of the city.They believe in something better than what’s currently out there. A place that celebrates life rather than sucks life out of it. A hotel that’s built on creativity and a belief that you don’t have to accept the conventional. Somewhere that sends you away with fun stories and ideas, and is easy on your pocket.
Show more...Investment focus
- Industry: Health Care, Biotechnology, AgTech
- Stage:Seed, Series B
- Geography: Belgium
Investor stats
- Total investments: 7
- Round size: Seed $3.7M–$11M; Series B $8.2M–$12M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- moveUP — Ontvang medische zorg op afstand voor en na uw operatie. moveUP is gespecialiseerd in de begeleiding van knie- en heupoperaties.
- Axithra — Axithra provides therapeutic medication monitoring and measures beta-lactam antibiotic concentrations in blood.
- Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Omnes Capital takes a unique approach to renewable energy, transforming developers into independent power producers to provide green energy to millions.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B
- Geography: France, Germany, United States
Investor stats
- Total investments: 185
- Round size: Series A $4.3M–$41M; Series B $4.4M–$53M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely actively investing — fresh fund, raised $132M in 2025
Portfolio highlights
- SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
- Adictiz — Adictiz, a French company founded in 2009 by Charles Christory, develops and publishes social games for the web and mobile phones.With successful brands including “Space Dog” and “What a Stupid Pigeon”, which attract close to 2.5 million players every month, Adictiz has established itself as an expert player in social and mobile gaming.Basedat the EuraTechnologies economic excellence hub in Lille, which is dedicated to serving information and communication technology companies, Adictiz set up Adictiz Studio in late 2011, which specialises in the creation of customised social games for brands. Adictiz Studio was recently selected by Facebook as a PMD (Preferred Marketing Developer).
- Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 398
- Round size: Series A $9.5M–$133M; Series B $15M–$135M; Series C $30M–$118M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Santaris Pharma — Spearheading RNA molecule research since 2003, our site in Copenhagen is focused on leading chemistry for targeting any type of transcribed RNA using short synthetic single-strand oligonucleotides. Here, our experts in the field pioneered our core technology platform of locked nucleic acids (LNA) and antisense oligonucleotides (ASO).
- PTC Therapeutics — Translating Science. Transforming Lives.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in the most promising life science companies.
Show more...Investment focus
- Industry: Biotechnology, Medical, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Belgium, The Netherlands
Investor stats
- Total investments: 41
- Round size: Series A $12M–$75M; Series B $29M–$130M; Series C $75M–$125M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $267M in 2021
Portfolio highlights
- Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.
- Unnatural Products — Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.Unnatural Products was founded in 2017 and is headquartered in Santa Cruz,California.
- Vaderis Therapeutics — Vaderis Therapeutics is a biotechnology company in the clinical stages that specializes in the treatment of uncommon and orphan diseases.
Baekeland Funds is a seed capital fund formed to invest in companies developed at the University of Ghent.
Show more...Investment focus
- Industry: Biotechnology, Hardware, Software
- Stage:Series B, Series C
- Geography: Belgium
Investor stats
- Total investments: 8
- Lead/follow: 0% lead, 100% follow
- Last fund: May invest from a new fund soon — raised $15M in 2005
Portfolio highlights
- Caliopa — Caliopa NV develops and markets silicon photonics based optical transceivers for the data and telecommunications markets. The company was incorporated in 2010 and is based in Zwijnaarde, Belgium.
- Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
- Trinean — Unchained Labs helps biologics & gene therapy researchers break free from tools that don't cut it. Crank up your research with our problem-solving products.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 108
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 48% lead, 52% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
- smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
- Cloverleaf Bio — Cloverleaf Bio | Developing a new class of RNA therapeutics to revolutionize cancer therapy.
UCB Ventures is a €150 million strategic corporate venture fund
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: United States, Belgium, Spain
Investor stats
- Total investments: 22
- Round size: Series A $7M–$75M; Series B $9.4M–$135M; Venture - Series Unknown $12M–$42M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- ViaNautis — Precision Solutions
- SonoThera — Explore therapeutic ultrasound for non-invasive, targeted genetic medicine delivery that improves precision and biodistribution. Learn more.
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Private Equity, Series B
- Geography: France, United States, Spain
Investor stats
- Total investments: 53
- Round size: Series A $5.7M–$23M; Series B $7.2M–$87M; Private Equity $23M–$150M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fresh fund, raised $383M in 2026
Portfolio highlights
- HEALTH IN CODE — HIC’s foundational mission is “the identification of health problems that may benefit from a genetic diagnosis, and the development and provision of genetic testing services for those conditions”. Since the beginning of the company, our main differential value is the combination of Knowledge Management tools with an expert dedicatedmultidisciplinary team, which allows us to provide a unique level of interpretation for the best genotyping.Currently HIC is specialized in high quality sequencing services and in the interpretation of genetic tests, providing clinicians with the tool to offer personalized medical care. HIC is the European leader on genetic diagnosis of inherited cardiovascular diseases and constantly extending its scope to other diseases: dyslipidemias, skeletal myopathies and most recently, cancer.
- Ona Therapeutics — Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
AgroSavfe nv, a Belgium-based agro-biotech company
Show more...Investment focus
- Industry: Biotechnology, Agriculture, AgTech
- Stage:Seed, Series B, Series A
- Geography: Belgium, United Kingdom, Switzerland
Investor stats
- Total investments: 21
- Round size: Seed $2.9M–$11M; Series A $8.4M–$9.3M; Series B $4.7M–$24M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Optiflux — Optiflux automatiseert het bewaarbeheer van vers fruit met slimme AI & vision-technologie. Minder verlies, meer winst voor teler & handelaar.
- Rainbow Crops — Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties.
- MoA Technology — We harness the principles of natural selection to accelerate discovery for better, safer herbicides so farmers can continue to feed the world.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 222
- Round size: Series A $19M–$180M; Series B $16M–$155M; Series C $19M–$111M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fresh fund, raised $606M in 2026
Portfolio highlights
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Solstice Oncology — Solstice Oncology is a clinical stage immuno-oncology company developing a therapeutic that meets cancer at its most vulnerable moment, before surgery, to drive deep pathological response and return patients to lasting health. The company's lead program is targeting colon cancer.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.Fund+ was established in 2015 and is based in Leuven, Belgium.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Belgium, United States, Spain
Investor stats
- Total investments: 34
- Round size: Series A $12M–$47M; Series B $22M–$125M; Series C $11M–$401M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Ona Therapeutics — Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!SFPIM investment firm that invests in technology and infrastructure.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Semiconductor
- Stage:Series A, Venture - Series Unknown
- Geography: Belgium, France, Switzerland
Investor stats
- Total investments: 26
- Round size: Series A $8.6M–$57M; Venture - Series Unknown $11M–$251M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- D-CRBN — D-CRBN recycles CO2 for industrials through our patented CCU plasma technology. We use plasma to convert CO2 emissions to useful chemical building blocks. Our plasma process splits CO2 molecules into their original building blocks to make e-fuels, chemicals, or polymers to ultimately achieve a circular and more sustainable economy. Battling global warming will be the toughest environmental challenge that our society has ever faced. We have set our objectives to help reduce CO2 emissions, reaching a carbon-neutral society by 2050. Launch your CO2 recycling initiative at your plant, go net-zero and join us to Sparc* the new industrial revolution.
- e-peas — Discover e-peas, pioneer of the Ambient IoT concept since 2014, which offers the most efficient energy harvesting pmics on the market to make your devices more energy self-sufficient: AEMs.
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 190
- Round size: Seed $495k–$5M; Series A $1.2M–$4.5M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Stylect — Stylect is a mobile app to to help women discover their perfect shoe. They aggregate products from multiple websites and based on users' preferences (that they gather through a hot-or-not interface), they recommend better products. Their users are able to keep track of and buy the products they like and receive notifications whenever a productthey love goes on sale. Finally, They use geolocation to let their users know when a shoe is selling in a store nearby.
- LockStyler — LockStyler is a hair locks coloring device used by hairdressers for hair highlighting and lowlighting. It is composed of an applicator, cartridge, and base. LockStyler was launched in 2014 and is manufactured in Montreux, Switzerland.
- Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.
Theodorus is the spin-off fund of Université Libre de Bruxelles that invests ininvest in early stage projects based on proprietary disruptive technologies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Seed, Venture - Series Unknown
- Geography: Belgium, Canada, France
Investor stats
- Total investments: 22
- Round size: Seed $67k–$18M; Series A $1.3M–$41M; Venture - Series Unknown $3.6M–$20M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Icentia — Icentia provides a range of innovative medical tests for healthcare institutions. They are able to offer valuable solutions for major problems in the field of medical testing.
- Simmunome AI — We use AI to create accurate, comprehensive disease models using multi-omic data to determine the probability of success of a drug. Our clinical trial simulations allow you to gain insights, make go/no-go decisions, and de-risk your pipeline, getting you to market faster and reducing your R&D co
- Ability biologics — Ability develops innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 738
- Round size: Seed $850k–$7M; Series A $3.1M–$31M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $515M in 2022
Portfolio highlights
- Zimory — Founded in 2007, Zimory provides carrier-grade cloud infrastructure management software that allows service providers, enterprises and cloud brokers to fully leverage the power and elasticity of cloud computing. Zimory’s intelligent Cloud Suite simplifies, automates and expedites the creation, launch and management of all types of cloudenvironments – whether public, private, virtual private or hybrid. Zimory software is also a key enabler of cloud marketplaces for enterprise services, applications and infrastructure. Headquartered in Berlin, Zimory has development centers in Erfurt, Germany and Minsk, Belarus, a subsidiary office in New York City and is expanding its expertise and presence globally.
- Alteva — Alteva develops battery cells for the decarbonisation of the global transport sector, and focus on high-energy density battery cells with high safety profiles specifically designed for the aviation and heavy-duty transport sectors.
- Smartblue — Smartblue develops and runs software and processes to monitor and optimize zero emission energy systems. As a hardware independent specialist Smartblue delivers a software service for the maintenance, life-cycle management, production forecasting and remote control of photovoltaic and energy storage systems all together in one centralized “SmartControl” Operations and Control Center web application. We help our customers drive down overall operational cost through automation, smart failure detection and big data analysis on imminent defects.
VIVES is a seed capital fund initiated by UCLouvain which invests in companies developing disruptive innovations with a positive societal impact.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: Belgium, France, Switzerland
Investor stats
- Total investments: 10
- Round size: Seed $2.9M–$5.5M; Series A $18M–$165M; Series B $34M–$132M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Bionyra — Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases.
- Generare — Exploring microbial chemistry. Building a library of nature-evolved molecules for discovery.
- Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: Ireland, United States, France
Investor stats
- Total investments: 57
- Round size: Series A $6.3M–$35M; Series B $5.5M–$68M; Series C $3.3M–$110M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $140M in 2019
Portfolio highlights
- Palyon Medical — Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.
- Neuromod Devices — Neuromod is the global medical device company that developed Lenire, the FDA Approved tinnitus treatment device.
- Vivasure Medical — Pioneering the Future of Large-Bore Vessel Closure for Arterial and Venous Access. The first and only 100% bio-absorbable, sutureless patch..
Inventures is a European venture capital fund that builds a better world through a portfolio of investments in sustainable businesses.The firm has two funds: Inventures I & Inventures II.Inventures was created to support early stage smart and innovative European businesses, to support sustainable job growth and empower entrepreneurs.Inventures empowers citizenship co-investments through a crowdfunding platform, MyMicroInvest.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Belgium, France, United Kingdom
Investor stats
- Total investments: 50
- Round size: Seed $67k–$2.1M; Series A $422k–$14M; Series B $165k–$21M
- Lead/follow: 8% lead, 92% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- BiOceanOr — BiOceanOr harnessed the power of Marine Biology and AI to deliver bio-guided services that optimize fish welfare and fish growth, while supporting aquaculture sustainability standards
- myskillcamp — Myskillcamp is a digital learning platform and educational design support service. Myskillcamp supports their customers in the digital transformation of their company and the launch of their Digital Learning project. From the audit of needs to the design of engaging educational devices, through a pilot phase, they make a point of honor to adapt thedigital to the specificities of each and give it meaning.With their online platform, businesses can manage their learner communities and connect all their partners in one place. Their tool also allows businesses to structure training spaces by skills, trades, brands within camps. In parallel, businesses can create educational content from scratch, select a map in their marketplace, or plan sessions in-class. Businesses can organize the distribution of their training to a single learner or to a whole group.
- Octave — Optimize energy use with Octave's battery storage (BESS) and energy management system (EMS). Reduce costs, increase flexibility.
AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: France, Spain, Belgium
Investor stats
- Total investments: 32
- Round size: Seed $2.2M–$18M; Series A $18M–$37M; Venture - Series Unknown $2.2M–$16M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $116M in 2021
Portfolio highlights
- Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
- ARTHEx Biotech — ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing advanced RNA treatments against genetic diseases.
- Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
Shaping new life-science ventures.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Health Care
- Stage:Series A, Seed
- Geography: The Netherlands, United States, Belgium
Investor stats
- Total investments: 66
- Round size: Seed $1.1M–$50M; Series A $6M–$86M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $172M in 2021
Portfolio highlights
- Dualyx — Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
- Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
- Noviogendix Holding — NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer. NovioGendix, based in Nijmegen (The Netherlands), is a molecular diagnostic company providing an expert-based, integrated approach in developing advanced and clinically useful molecular diagnosticassays for uro-oncological practice. NovioGendix has a range of diagnostic tests for prostate, bladder, kidney and other urologic cancers in various stages of development. Commencing activities in 2008 as a Radboud University Medical Center (Radboudumc) spin-off company, NovioGendix has a standing cooperation with various Radboudumc departments. The main shareholders of NovioGendix include BioGeneration Ventures, and Participatiemaatschappij Oost Nederland.
Lilly is a medicine company that puts health above all. Learn about our medicines, view condition support, find care, and much more.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 111
- Lead/follow: no public data
Portfolio highlights
- Excelsior Sciences — Rebuilding the World, From the Bottom Up
- Syndeio Biosciences — Syndeio Biosciences is a clinical-stage biotechnology company focused on developing therapies to restore and enhance synaptic health in central nervous system (CNS) disorders.
- Affinia Therapeutics — Affinia Therapeutics is expanding what's possible in adeno-associated virus (AAV) gene therapy today and bringing transformative medicines for people.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!invest.bw is a venture capital firm.
Show more...Investment focus
- Industry: Health Care, Neuroscience
- Stage:Seed
- Geography: United States
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- BiocSol — BiocSol focus on sustainable microbial-based crop protection.
- neuroClues — An easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam
- ARK Capture Solutions — ARK Capture Solutions is a cleantech company that specializes in decarbonization solutions to record low energy consumption.
Leading venture capital fund with exclusive focus on micro/nano-electronics and advanced materials
Show more...Investment focus
- Industry: Software, Manufacturing, Semiconductor
- Stage:Series B, Series A
- Geography: Belgium, United States, Germany
Investor stats
- Total investments: 20
- Round size: Series A $3.3M–$26M; Series B $7.5M–$13M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Accelleran — Accelleran is pioneering a disruptive approach to the delivery of cost-effective, carrier and mission-critical grade TDD and FDD Small Cell networks through its focus on software quality and partnerships with volume manufacturers.Accelleran provides LTE Small Cell software and LTE Small Cell product solutions which address the real-worldchallenges of volume deployment of Small Cells. We offer turnkey solutions and unique experience on the challenges of integrating cellular technology on low cost, yet powerful platforms and architectures. Accelleran offers its customers solid and dependable system solutions, backed by the support of our unparalleled expertise.Accelleran’s technology is genuinely independent from any HW platform and enables operators to invest once in the integration and validation of a common software base that can be deployed across different segments, platforms and Small Cell architectural approaches to enable a truly integrated HetNet.
- Silicon Line — Munich, Germany-based Silicon Line (www.silicon-line.com) is the unchallenged world leader in developing and providing innovative ultra-low-power optical link technology that enables the use of thin, long, lightweight and very high speed ‘active’ optical cables for a wide array of consumer electronics products – including TVs, set-top boxes, videogame consoles, augmented reality (AR) and virtual reality (VR) headsets and related devices – as well as commercial and industrial applications. ‘Active’ refers to powered electronics integrated within the cable.Clear evidence of Silicon Line’s global leadership in ultra-lower-power optical technology can be seen not only by its steadily evolving line of leading-edge and industry-first products – with more than 25 different products now in use – but also in its pivotal role within the HDMI Forum, where it has successfully led efforts to enhance support for active optical cable technology standards in the latest specification, HDMI 2.1.Founded in 2005 as an outsource integrated circuit (IC) design house, Silicon Line quickly developed proven expertise in ultra-low-power, analog and mixed-signal chip design. Billions of ICs based on its designs have been used in products of major brand-name manufacturers.
- Silicon Mobility — Our solution enables carmakers to improve EV and HEV energy efficiency, increase range and accelerate charging time while reducing cost.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 174
- Round size: Seed $2.4M–$24M; Series A $5.6M–$50M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Cyllene Therapeutics — EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- ApoGen Biotechnologies — Explore fast payout casinos that deliver winnings instantly or under 24 hours. List of the best payout casinos to get same day winnings.
The Federal Holding and Investment Company (SFPI-FPIM) centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 42
- Round size: Series A $4.3M–$49M; Series B $12M–$75M; Series C $5.6M–$250M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- Cohabs — We create sustainable & community-driven shared homes around the world for young workers and interns. Join our community.
- Axelera AI — Axelera AI is a company that delivers purpose-built hardware and software platforms designed to accelerate artificial intelligence tasks, particularly in edge computing. The company's flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions.This platform has been recognized for its innovation, notably being named a CES® 2024 Innovation Awards Honoree.Incubated in 2019 by the emerging technologies leader Bitfury and joined by the leading nano-technology group imec in early 2020, Axelera AI launched as a new company in 2021. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AI has R&D offices in Belgium, Switzerland, and Italy. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies.
- Tangent Works — Create predictive models in seconds for faster and better forecasting & anomaly detection with TIM InstantML.
Quest for Growth (QGPLF) is an Internet company located in 19 Lei, Leuven, Flanders, Belgium.
Show more...Investment focus
- Industry: Biotechnology, Hardware, Software
- Stage:Series B, Series C
- Geography: Belgium, France, The Netherlands
Investor stats
- Total investments: 24
- Round size: Series B $510k–$65M; Series C $8.1M–$21M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Qpinch — Our patented QHT - Qpinch Heat Transformer - technology recovers and transforms waste heat into carbon neutral process heat.
- Finquest — Tap into the largest private company database in the world to change the way you find and connect with M&A targets using Data, AI, & People.
- Confo Therapeutics — Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, France, Switzerland
Investor stats
- Total investments: 217
- Round size: Series A $7.3M–$115M; Series B $15M–$150M; Series C $15M–$94M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $650M in 2016
Portfolio highlights
- NextCure — NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.
- Spark Therapeutics — Breakthrough science. One moment, one day, one person at a time.
- Marinus Pharmaceuticals — Marinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, offering a new mechanism of action with demonstrated safety and convenient dosing for patients affected by epilepsy and CNS disorders.
New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companiesusing science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series D
- Geography: United States, United Kingdom, Belgium
Investor stats
- Total investments: 88
- Round size: Series A $4M–$49M; Series B $8M–$52M; Series D $5M–$38M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $24M in 2021
Portfolio highlights
- Glydways — Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs.
- EXTEN Technologies — EXTEN HyperDynamic software platform solves the primary challenges of today's data centers: the necessity of keeping up with surging data density, velocity, and volume requirements, and the need for increased application agility.
- Trellis Bioscience — Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact ofpotential therapeutic interventions. The company is based in San Francisco, California.
We empower high-potential entrepreneurship and democratize venture capital. Discover promising start-ups & SMEs and invest alongside business angels.
Show more...Investment focus
- Industry: Information Technology, E-Commerce, Health Care
- Stage:Series A, Seed, Pre-Seed
- Geography: Belgium, France
Investor stats
- Total investments: 16
- Round size: Seed $165k–$1.3M; Pre-Seed $150k–$197k; Series A $247k–$2.5M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Jelloow — Jelloow your virtual marketing navigator. Matching brands with likeminded marketing agencies.
- PlayTreks — Supercharge your music business with PlayTreks, the all-in-one workspace for music professionals. Built for indie artists, artist managers and label teams.
- NietsCo — NietsCo. is the home of Botaniets Gin 0.0%, a leading selection of alcohol-free products, carefully distributed to the world's best restaurants, concept stores, shops and consumers.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 329
- Round size: Series A $6.6M–$70M; Series B $10M–$109M; Series C $12M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
- Comet Biorefining — Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosicglucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
Vinnof is a venture capital firm that offers seed capital to innovative, early-stage startups based in Flanders, Belgium.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Belgium, United Kingdom
Investor stats
- Total investments: 5
- Round size: Series A $9.3M–$11M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Loshai — Loshai is a unified Predictive platform that allows that allows data integration, modelling and visualisation using no-code tools . It provides 360 analytics insights on data along with simulations based o what-if scenarios using AI loops. LoshAi's simple UI allows mapping just enough data to answer the business questions at hand. Schema-lessintegration across OT and IT sources.
- Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
- Okapi Sciences — Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination ofindividuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.
Biotechnology Investor funding in Belgium at a glance
Stats across 294 deals from 320 investors.
Access all 320 investors in Belgium Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Investors in Belgium investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 320 investors investing in Belgium Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!